HLA and melanoma: Multiple alterations in HLA class i and II expression in human melanoma cell lines from ESTDAB cell bank

Cancer Immunology, Immunotherapy

Volumn 58, Issue 9, 2009, Pages 1507-1515

  Mendez, Rosa ^a   Aptsiauri, Natalia ^a   Del Campo, Ana ^a   Maleno, Isabel ^a   Cabrera, Teresa ^a,b   Ruiz Cabello, Francisco ^a,b   Garrido, Federico ^a,b   Garcia Lora, Angel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

ESTDAB; HLA class I and II; Melanoma; Tumour

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; CELL LINE; CELL SURFACE; CHROMOSOME 6; GENE LOCUS; GENE MUTATION; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; DATABASES, FACTUAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MELANOMA;

EID: 67649657641     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0701-z     Document Type: Review

References (57)

1. M Altomonte E Fonsatti A Visintin M Maio 2003 Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 22 6564 6569 (Pubitemid 37372336)
2. A Anichini R Mortarini D Nonaka A Molla C Vegetti E Montaldi X Wang S Ferrone 2006 Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients Cancer Res 66 6405 6411
3. N Aptsiauri R Carretero A Garcia-Lora LM Real T Cabrera F Garrido 2008 Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations Cancer Immunol Immunother 57 1727 1733
4. R Benitez D Godelaine MA Lopez-Nevot F Brasseur P Jiménez M Marchand MR Oliva N van Baren T Cabrera G Andry C Landry F Ruiz-Cabello T Boon F Garrido 1998 Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides Tissue Antigens 52 520 529 (Pubitemid 29002755)
5. MS Brady F Lee H Petrie DD Eckels JS Lee 2000 CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro Cancer Immunol Immunother 48 621 626 (Pubitemid 30064664)
6. T Cabrera F Ruiz-Cabello F Garrido 1995 Biological implications of HLA-DR expression in tumours Scand J Immunol 41 398 406
7. T Cabrera M Angustias Fernandez A Sierra A Garrido A Herruzo A Escobedo A Fabra F Garrido 1996 High frequency of altered HLA class I phenotypes in invasive breast carcinomas Hum Immunol 50 127 134 (Pubitemid 26337114)
8. T Cabrera E Lara JM Romero I Maleno LM Real F Ruiz-Cabello P Valero FM Camacho F Garrido 2007 HLA class I expression in metastatic melanoma correlates with tumour development during autologous vaccination Cancer Immunol Immunother 56 709 717 (Pubitemid 46348739)
9. J Dengjel MD Nastke C Gouttefangeas G Gitsioudis O Schoor F Altenberend M Müller B Krämer A Missiou M Sauter J Hennenlotter D Wernet A Stenzl HG Rammensee K Klingel S Stevanović 2006 Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas Clin Cancer Res 12 4163 4170
10. L Derré M Corvaisier B Charreau A Moreau E Godefroy A Moreau-Aubry F Jotereau N Gervois 2006 Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells J Immunol 177 3100 3107 (Pubitemid 44277827)
11. A Garcia-Lora I Algarra F Garrido 2003 MHC class I antigens, immune surveillance, and tumour immune escape J Cell Physiol 195 346 355 (Pubitemid 36529863)
12. F Garrido T Cabrera A Concha S Glew F Ruiz-Cabello PL Stern 1993 Natural history of HLA expression during tumour development Immunol Today 14 491 499 (Pubitemid 23301000)
13. F Garrido F Ruiz-Cabello T Cabrera JJ Pérez-Villar M López-Botet M Duggan-Keen PL Stern 1997 Implications for immunosurveillance of altered HLA class I phenotypes in human tumours Immunol Today 18 89 95 (Pubitemid 27107103)
14. Garrido F, Cabrera T, Acolla RS, Bensa JC, Bodmer W, Dohr G, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades Crh, Salvaneschi L, Stern PL, Ziegler A (1997) HLA and cancer: 12th international histocompatibility workshop study. In: Charron D (ed) HLA, genetic diversity of HLA. Functional and medical implications, vol 1. EDK, p 445
15. F Garrido I Algarra 2001 MHC antigens and tumor escape from immune surveillance Adv Cancer Res 83 117 158 (Pubitemid 32959264)
16. G Gastl T Ebert CL Finstad J Sheinfeld A Gomahr W Aulitzky NH Bander 1996 Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma J Urol 155 361 367 (Pubitemid 126426495)
17. EC Ibrahim Y Allory F Commo B Gattegno P Callard P Paul 2003 Altered pattern of major histocompatibility complex expression in renal carcinoma: tumour-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma Am J Pathol 162 501 508 (Pubitemid 36267857)
18. T Kageshita S Hirai T Ono DJ Hicklin S Ferrone 1999 Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression Am J Pathol 154 745 754 (Pubitemid 29122593)
19. T Kageshita T Ishihara M Campoli S Ferrone 2005 Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions Tissue Antigens 65 419 428 (Pubitemid 40592936)
20. J Klein A Sato 2000 The HLA system. First of two parts N Engl J Med 343 702 709 (Pubitemid 30679953)
21. H Kobayashi T Nagato K Sato N Aoki S Kimura M Murakami H Iizuka M Azumi H Kakizaki M Tateno E Celis 2007 Recognition of prostate and melanoma tumour cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner Cancer Res 67 5498 5504 (Pubitemid 46997291)
22. LA Koopman WE Corver AR van der Slik MJ Giphart GJ Fleuren 2000 Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer J Exp Med 191 961 976
23. P Larrieu LH Ouisse Y Guilloux F Jotereau JF Fonteneau 2007 A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumour cells to CD4+ T lymphocytes Cancer Immunol Immunother 56 1565 1575 (Pubitemid 47094385)
24. S LeibundGut-Landmann JM Waldburger M Krawczyk LA Otten T Suter A Fontana H Acha-Orbea W Reith 2004 Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes Eur J Immunol 34 1513 1525 (Pubitemid 39256032)
25. P Li JL Gregg N Wang D Zhou P O'Donnell JS Blum VL Crotzer 2005 Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing Immunol Rev 207 206 217 (Pubitemid 41415019)
26. C Maccalli YF Li M El-Gamil SA Rosenberg PF Robbins 2003 Identification of a colorectal tumour-associated antigen (COA-1) recognized by CD4(+) T lymphocytes Cancer Res 63 6735 6743 (Pubitemid 37322953)
27. B Mach V Steimle E Martinez-Soria W Reith 1996 Regulation of MHC class II genes: lessons from a disease Annu Rev Immunol 14 301 331 (Pubitemid 26130187)
28. I Maleno MA López-Nevot T Cabrera J Salinero F Garrido 2002 Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 Cancer Immunol Immunother 51 389 396 (Pubitemid 35002044)
29. I Maleno CM Cabrera T Cabrera L Paco MA López-Nevot A Collado A Ferrón F Garrido 2004 Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 Immunogenetics 56 244 253 (Pubitemid 39119279)
30. I Maleno JM Romero T Cabrera L Paco N Aptsiauri JM Cozar M Tallada MA López-Nevot F Garrido 2006 LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas Immunogenetics 58 503 510 (Pubitemid 44025525)
31. M Mandic F Castelli B Janjic C Almunia P Andrade D Gillet V Brusic JM Kirkwood B Maillere HM Zarour 2005 One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma J Immunol 174 1751 1759
32. R Marín F Ruiz-Cabello S Pedrinaci R Méndez P Jiménez DE Geraghty F Garrido 2003 Analysis of HLA-E expression in human tumours Immunogenetics 54 767 775 (Pubitemid 36384471)
33. FM Marincola EM Jaffee DJ Hicklin S Ferrone 2000 Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Adv Immunol 74 181 273
34. K Matsushita T Takenouchi H Shimada T Tomonaga H Hayashi A Shioya A Komatsu H Matsubara T Ochiai 2006 Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-gamma in situ Cancer Sci 97 57 63 (Pubitemid 43257028)
35. AM Mehta ES Jordanova GG Kenter S Ferrone GJ Fleuren 2008 Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma Cancer Immunol Immunother 57 197 206 (Pubitemid 350159921)
36. M Meissner TE Reichert M Kunkel W Gooding TL Whiteside S Ferrone B Seliger 2005 Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome Clin Cancer Res 11 2552 2560 (Pubitemid 40569453)
37. R Méndez T Rodríguez A Del Campo E Monge I Maleno N Aptsiauri P Jiménez S Pedrinaci G Pawelec F Ruiz-Cabello F Garrido 2008 Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines Cancer Immunol Immunother 57 719 729 (Pubitemid 351641032)
38. Y Mizukami K Kono T Maruyama M Watanabe Y Kawaguchi K Kamimura H Fujii 2008 Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma Br J Cancer 99 1462 1467
39. D Nagorsen C Scheibenbogen FM Marincola A Letsch U Keilholz 2003 Natural T cell immunity against cancer Clin Cancer Res 9 4296 4303 (Pubitemid 37248383)
40. L Novellino C Castelli G Parmiani 2005 A listing of human tumour antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 187 207 (Pubitemid 40174238)
41. A Paschen M Song W Osen XD Nguyen J Mueller-Berghaus D Fink N Daniel M Donzeau W Nagel H Kropshofer D Schadendorf 2005 Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice Clin Cancer Res 11 5241 5247 (Pubitemid 41003712)
42. G Pawelec S Marsh 2006 ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank Cancer Immunol Immunother 55 623 627 (Pubitemid 43312157)
43. LM Ramal I Maleno T Cabrera A Collado A Ferron MA Lopez-Nevot F Garrido 2000 Molecular strategies to define HLA haplotype loss in microdissected tumour cells Hum Immunol 61 1001 1012 (Pubitemid 30945335)
44. LM Real T Cabrera A Collado P Jimenez A Garcia F Ruiz-Cabello F Garrido 1999 Expression of HLA G in human tumors is not a frequent event Int J Cancer 81 4 512 518 (Pubitemid 29203045)
45. W Reith S LeibundGut-Landmann JM Waldburger 2005 Regulation of MHC class II gene expression by the class II transactivator Nat Rev Immunol 5 793 806 (Pubitemid 41400853)
46. LM Rimsza RA Roberts TP Miller JM Unger M LeBlanc RM Braziel DD Weisenberger WC Chan HK Muller-Hermelink ES Jaffe RD Gascoyne E Campo DA Fuchs CM Spier RI Fisher J Delabie A Rosenwald LM Staudt TM Grogan 2004 Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumour immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project Blood 103 4251 4258 (Pubitemid 38685371)
47. PF Robbins M El-Gamil YF Li G Zeng M Dudley SA Rosenberg 2002 Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumour-infiltrating lymphocytes from a patient with melanoma J Immunol 169 6036 6047 (Pubitemid 35291712)
48. T Rodríguez R Méndez A Del Campo P Jiménez N Aptsiauri F Garrido F Ruiz-Cabello 2007 Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines BMC Cancer 7 34
49. T Rodríguez R Méndez A Del Campo N Aptsiauri J Martín G Orozco G Pawelec D Schadendorf F Ruiz-Cabello F Garrido 2007 Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines Immunogenetics 59 123 133 (Pubitemid 46130791)
50. TA Röhn A Reitz A Paschen XD Nguyen D Schadendorf AB Vogt H Kropshofer 2005 A novel strategy for the discovery of MHC class II-restricted tumour antigens: identification of a melanotransferrin helper T-cell epitope Cancer Res 65 10068 10078 (Pubitemid 41541489)
51. P Rolland S Deen I Scott L Durrant I Spendlove 2007 Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer Clin Cancer Res 13 3591 3596 (Pubitemid 46955120)
52. K Sabapathy SY Nam 2008 Defective MHC class I antigen surface expression promotes cellular survival through elevated ER stress and modulation of p53 function Cell Death Differ 15 1364 1374
53. FM Speetjens EC de Bruin H Morreau EC Zeestraten H Putter JH van Krieken MM van Buren M van Velzen NG Dekker-Ensink CJ van de Velde PJ Kuppen 2008 Clinical impact of HLA class I expression in rectal cancer Cancer Immunol Immunother 57 601 609 (Pubitemid 351641023)
54. PJ van den Elsen SJ Gobin MC van Eggermond A Peijnenburg 1998 Regulation of MHC class I and II gene transcription: differences and similarities Immunogenetics 48 208 221 (Pubitemid 28352187)
55. SG van Duinen DJ Ruiter EB Broecker EA van der Velde C Sorg K Welvaart S Ferrone 1988 Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma Cancer Res 48 1019 1025 (Pubitemid 18061905)
56. IS van Houdt BJ Sluijter LM Moesbergen WM Vos TD de Gruijl BG Molenkamp AJ van den Eertwegh E Hooijberg PA van Leeuwen CJ Meijer JJ Oudejans 2008 Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumour infiltrating T-lymphocytes and preserved MHC class I antigen expression Int J Cancer 123 609 615 (Pubitemid 351898419)
57. NF Watson JM Ramage Z Madjd I Spendlove IO Ellis JH Scholefield LG Durrant 2006 Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis Int J Cancer 118 6 10 (Pubitemid 41681574)